GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company specializing in vaccines and immunotherapies, has announced a private placement financing expected to generate gross proceeds of approximately $3 million. The company entered into a securities purchase agreement with existing institutional investors for the sale of 2,027,027 shares of common stock (or equivalents) along with Series A and Series B warrants, each to purchase up to 2,027,027 shares of common stock at an exercise price of $1.48 per share. The Series A warrants have a five-year term, while the Series B warrants have an 18-month term.
The offering is priced at-the-market under Nasdaq rules and is expected to close on or about May 19, 2026, subject to customary conditions. Net proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent. The securities are being offered in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Regulation D, and the company has agreed to file a registration statement with the SEC covering the resale of the shares and underlying shares.
This financing arrives at a critical juncture for GeoVax, which is advancing several key programs. The company's priority program, GEO-MVA, is a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. It is progressing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026. This program addresses critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings.
GeoVax’s broader pipeline includes GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised and other patient populations. The company maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.
The implications of this financing are significant for GeoVax's ability to advance its clinical programs. The $3 million infusion provides working capital to support the upcoming Phase 3 trial for GEO-MVA, which could address ongoing global health concerns related to mpox and smallpox. Additionally, it supports the continued development of Gedeptin for head and neck cancer, potentially offering new treatment options for patients. The involvement of existing institutional investors signals confidence in GeoVax's pipeline and strategy. As the company progresses its trials, the outcomes could impact biodefense preparedness and oncology treatment paradigms, making this financing a key step in its development trajectory.
